Can a Two-Drug combo stop colorectal cancer from coming back?

This phase 3 trial is testing whether the experimental drug zanzalintinib, alone or combined with an immunotherapy (pembrolizumab plus berahyaluronidase alfa), can improve disease-free survival in people with stage II or III colorectal cancer who have molecular residual disease (MRD) after completing definitive therapy. Participants have no visible cancer on scans but test positive for circulating tumor DNA (ctDNA), indicating a higher risk of recurrence. The study compares these treatments against a placebo to see if they can delay or prevent the cancer from returning.